

**Preferential Association of Hepatitis C Virus with CD19+ B Cells Is
Mediated by Complement System**

Richard Y. Wang¹, Patricia Bare^{1,2}, Valeria De Giorgi¹, Kentaro Matsuura^{1, 3}, Kazi
Abdus Salam^{1, 4}, Teresa Grandinetti¹, Cathy Schechterly¹, Harvey J. Alter¹

¹Department of Transfusion Medicine, Clinical Center, National Institutes of
Health, Bethesda, MD; ²Instituto de Investigaciones Hematológicas, Instituto de
Medicina Experimental, CONICET, Academia Nacional de Medicina, Buenos
Aires, Argentina; ³Department of Gastroenterology and Metabolism, Nagoya City
University Graduate School of Medical Sciences, Nagoya, Japan; ⁴Department of
Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205,
Bangladesh

Keywords: HCV, complement, B cell, CD21, Raji.

Corresponding author: Harvey J. Alter, Department of Transfusion Medicine,
Bldg. 10, Room 1C-711, NIH, 10 Center Drive, Bethesda, MD 20892. E-mail:

HAlter@cc.nih.gov

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.28842

List of Abbreviations:

HCV, hepatitis C virus; PBMCs, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; B-NHL, B-cell non-Hodgkin's lymphoma; Dpl, depleted; CR1/CD35, complement receptor 1; CR2/CD21, complement receptor 2; qPCR, quantitative real-time reverse-transcription polymerase chain reaction.

Financial support: This research was supported by the Intramural Research Program of Warren G. Magnuson Clinical Center, NIH.

Potential conflict of interest: Nothing to report.

This manuscript consists of a total of 5107 words of text (including references, excluding abstract and figure legends), 271 words of abstract, 8 figures, 48 references, and one supporting file.

Abstract

Extrahepatic disease manifestations are common in chronic hepatitis C virus (HCV) infection. The mechanism of HCV-related lymphoproliferative disorders is not fully understood. Recent studies have found that HCV in peripheral blood mononuclear cells (PBMCs) from chronically infected patients is mainly associated with CD19+ B cells. To further elucidate this preferential association of HCV with B cells, we used in vitro cultured virus and uninfected PBMCs from healthy blood donors to investigate the necessary serum components that activate the binding of HCV to B cells. First, we found that the active serum components were present not only in HCV carriers, but also in HCV recovered patients and HCV negative healthy blood donors and that the serum components were heat labile. Second, the preferential binding activity of HCV to B cells could be blocked by anti-complement C3 antibodies. In experiments with complement-depleted serum and purified complement proteins, we demonstrated that complement proteins C1, C2, and C3 were required to activate such binding activity. Complement protein C4 was partially involved in this process. Third, using antibodies against cell surface markers, we showed that the binding complex mainly involved CD21 (complement receptor 2), CD19, CD20, and CD81; CD35 (complement receptor 1) was involved but had lower binding activity. Fourth, both anti-CD21 and anti-CD35 antibodies could block the binding of patient-derived HCV to B cells. Fifth,

complement also mediated HCV binding to Raji cells, a cultured B cell line derived from Burkitt's lymphoma. *Conclusion:* In chronic HCV infection, the preferential association of HCV with B cells is mediated by the complement system, mainly through complement receptor 2 (CD21), in conjunction with the CD19 and CD81 complex.

Introduction

An estimated 180 million individuals are infected with hepatitis C virus (HCV) worldwide (1). More than 75% of HCV infections become persistent and may eventually lead to cirrhosis and hepatocellular carcinoma in 20% - 40%. A broad spectrum of extrahepatic manifestations is also associated with chronic HCV infection, including mixed cryoglobulinemia, cutaneous vasculitis, and B-cell non-Hodgkin's lymphoma (B-NHL) (2-5). Although there are several reports suggesting extrahepatic replication of HCV, particularly in PBMCs, even in some patients who appear to have resolved their infection (6-9), the existence of extrahepatic reservoirs of HCV replication remains highly controversial (10, 11).

Although the major site of HCV replication is in the liver, HCV RNA has been detected in association with peripheral blood mononuclear cells (PBMCs) (7, 10), and is particularly enriched in CD19+ B cells (10, 12, 13). Several factors have been shown to play important roles in HCV entry into susceptible cells (14-18), including CD81, scavenger receptor SR-BI, and the tight-junction protein Claudin-1. All three entry factors are required for infection of Huh-7.5 cells by cell culture-produced infectious HCV particles (16). However, all PBMC subsets lack at least one of these known HCV entry factors (16). CD81 is a widely distributed cell-surface tetraspanin that participates in different molecular complexes on various cell types, including B, T, and natural killer cells (16) and

has been proposed as the primary mediator of HCV binding to B cells (17, 18).

In human B cells, CD81 is known to form a costimulatory complex with CD19 and complement receptor 2 (CD21) (19). Co-ligation of the B cell antigen receptor (BCR) with this costimulatory complex can lower the threshold required for BCR-mediated B cell proliferation (20). Because all major subsets of PBMCs have high level expression of CD81 (18), CD81 alone could not account for the preferential association of HCV with B cells.

In this study, we used cell culture-produced HCV particles, pre-incubated with serum components plus various factors, followed by mixing with PBMCs from healthy blood donors. After separating PBMC into B cell and non-B cell fractions by CD19 magnetic microbeads, quantification of HCV RNA was carried out by real-time reverse-transcription polymerase chain reaction (qPCR) to measure the quantities of HCV binding to B cells. We sought to investigate the mechanism of preferential association of HCV with B cells in PBMCs from chronic HCV carriers, and to identify specific cell surface receptors involved in the binding process.

Patients and Methods

Patients:

Consenting blood donors identified as anti-HCV positive by enzyme immunoassay at the time of routine blood donation at the Department of Transfusion Medicine, National Institutes of Health (NIH) or the Greater Chesapeake and Potomac Region of the American Red Cross were enrolled in an NIH prospective study of the natural history of HCV infection (10). Ethics committees of the American Red Cross and the NIH approved the study protocol in accordance with the Declaration of Helsinki and the study has been reviewed annually by an NIH Institutional Review Board (NIH Protocol 91-CC-0017). All subjects gave written informed consent to participate in the study.

Methods:

A detailed description of methods used for cell culture, in vitro RNA synthesis, HCV production in cell culture, conversion of plasma to serum, PBMC isolation, part of in vitro HCV binding assay, and HCV detection can be found in Supporting Information.

In vitro HCV binding assay

In a standard binding assay, 3 ml of virus (1×10^7 genomic copies for HCV genotype 1a virus) was mixed with 100 μ l of serum sample (about 20-25 CH50 units) to initiate complement activation and incubated at 25°C for 1 h or at 37°C

for 0.5 h, followed by adding 2 ml of PBMCs ($4-5 \times 10^7$ cells) to the mixture and incubating for 1 h. The reaction was carried out in 50 ml sterile tubes with occasional mixing. After incubation, the cells were pelleted by centrifugation, washed once with 10 ml 1X PBS, pH7.4, centrifuged again, and re-suspended in 400 μ l of MACS buffer (Miltenyi Biotec Inc., Auburn, CA) supplemented with 0.5% bovine serum albumin. The cells were mixed with 100 μ l of mouse anti-human CD19 magnetic microbeads and incubated at 4°C for 20 min. The cells were then diluted with 10 ml MACS buffer, collected by centrifugation, and re-suspended in 1 ml MACS buffer. The cell suspension was applied to a MS column (Miltenyi Biotec Inc., Auburn, CA) on a magnetic field separator. The column was washed three times with 1 ml MACS buffer each time. The column was separated from the magnetic stand and placed on a 2 ml sterile tube. The CD19+ B cells were flushed from the column with 1 ml MACS buffer, collected by centrifugation, and re-suspended in 650 μ l of RNeasy Plus lysis buffer (Qiagen, Chatsworth, CA) supplemented with 1% 2-mercaptoethanol. RNA isolation was carried out by using RNeasy Plus mini kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions, and each sample was eluted from the column with 50 μ l of nuclease-free water (Thermo Fisher Scientific, Waltham, MA) supplemented with 1.0 mM dithiothreitol and 200 unit/ml RNAsin (Promega, Madison, WI).

Statistical analysis

Quantitative analysis of HCV genome copy number assessed by qPCR is expressed as the mean \pm standard deviation. An unpaired Student's *t*-test was used to determine the statistical significance. Values of $P < 0.05$ were judged significant. Data analysis and graphs were performed with GraphPad Prism 5 (GraphPad Software, La Jolla, CA).

RESULTS

Serum components from both HCV recovered patients and healthy blood donors can promote HCV binding to B cells.

To investigate the mechanism of preferential association of HCV with B cells in PBMC from chronic patients, we used in vitro cultured HCV virus (H77s, HCV genotype 1a) and B-cell enriched fractions from healthy donors to determine which serum components are necessary for promoting HCV binding to B cells. In the absence of serum, binding of HCV particles derived from in vitro cell culture was minimal in our in vitro assay system (data shown in Fig.1 legend and Fig. 2). When cell culture-produced HCV particles were pre-incubated with human serum samples, the viral particles attached to B cells with more than 100-fold efficiency as compared to that without serum treatment. As shown in Fig.1, serum samples from both HCV recovered patients and healthy blood donors contained such enhancing activity. This result indicated that the enhancement of HCV binding to

B cells by serum was independent of HCV infection and inherent in normal human serum. We also found significant variation among individuals of the enhancing activity present in their serum samples.

Heat-labile components in human serum promote the binding of HCV to B cells.

During the investigation period, we observed that the activity promoting HCV binding to B cells present in the serum samples was quickly lost even when the serum samples were stored at 4°C. Therefore, we measured the sensitivity of HCV binding activity to B cells by incubating serum samples at 56°C for 30 min first before mixing with virus. About 90% of HCV binding activity to B cells was lost after heat treatment as compared to the untreated serum samples (Fig. 2).

Antibodies against complement C3 protein can block HCV binding to B cells.

Since complement activity is well known for heat sensitivity, we tested whether the available antibodies against complement C3 protein could block the binding of HCV to B cells in our assay system. As shown in Fig.3, several anti-C3 antibodies, such as anti-C3 (C-4), anti-C3 (2898), and anti-C3d, had significant blocking activity against HCV binding to B cells, particularly, anti-C3d showed the

strongest blocking activity. However, because of the abundance of C3 protein in serum, when lowering the amount of C3d antibody, the blocking activity was gradually decreased (Supporting Fig. S1). Anti-C3 (B-9) antibody did not show blocking activity against HCV binding to B cells in our assay system. This may be because the epitope recognized by this antibody was not accessible in this assay.

Purified complement proteins added to the complement-depleted serum can restore HCV binding to B cells.

To further demonstrate the complement system is responsible for promoting the binding of HCV to B cells, we obtained several commercially available complement-depleted serum samples and purified complement proteins to reconstitute the binding experiment. As shown in Fig. 4, when binding of HCV was performed with C1, C2 or C3 depleted serum samples, the binding activity could hardly be detected. After adding the respective purified complement protein back to the reaction mixture, the binding activity of HCV to B cells was restored. In the absence of serum, none of the purified complement proteins alone had the ability to promote HCV binding to B cells. These results suggested that complement C1, C2, and C3 proteins are absolutely required for activating HCV to attach to B cells. When complement C4 depleted serum was tested, about 40% binding activity was detected as compared to the complete system with C4 depleted serum plus purified C4 protein (Fig. 4). Purified C4 protein alone did not

promote HCV binding to B cells. Therefore, complement C4 plays a lesser role in the binding of HCV to B cells compared to complement C1, C2 and C3. These results indicated that the classical complement activation pathway is involved in promoting the binding of HCV to B cells. When we mixed purified proteins of C1, C2, C3, and C4 together in the absence of serum, we were able to show enhancement of HCV binding to B cells (Supporting Fig. S2). Using complement C5 depleted serum and purified C5 protein to assay the HCV binding activity to B cells, demonstrated that C5 is not required for HCV binding to B cells. Indeed, when excess of C5 protein was added to the C5-depleted serum, the binding of HCV to B cells was significantly decreased (Fig. 4).

Receptors involved in complement-mediated HCV binding to B cells.

The above results indicated that the preferential association of HCV with B cells in PBMC from chronically infected patients is likely mediated by the complement system. In B cells, complement receptor 2 (CD21) is most abundant and usually forms a complex with CD19 and CD81, followed by complement receptor 1 (CD35). Using a battery of antibodies against complement-related receptors, we demonstrated that anti-CD21 had the strongest blocking activity for HCV binding to B cells (Fig. 5); this was consistent at varying concentrations of antibody ranging from 1 μ g to 10 μ g (Supporting Fig. S3 and S4). In addition, we showed that CD19 (Supporting Fig. S5) or CD20 (Fig. 5) are also involved in HCV binding

to B cells. For CD81, about 60% (6 out of 10) of PBMCs isolated from healthy blood donors showed inhibitory activity upon treatment of PBMC with anti-CD81.

Anti-CD21 and anti-CD35 antibodies can block B cell binding of HCV viruses derived from chronically infected patients.

To demonstrate that the preferential binding of HCV to B cells mediated by the complement system is not limited to cell culture derived virus, we repeated the B-cell binding experiments using the serum from three chronically infected patients as the source of virus and complement. In patients #1 and #2, both anti-CD21 and anti-CD35 antibodies inhibited HCV binding to B cells with anti-CD21 showing stronger activity. In patient #3, only anti-CD21 showed significant inhibitory activity (Fig. 6).

Complement-mediated HCV binding to B cells using in vitro cultured HCV 1a and HCV 2a viruses.

We further investigated whether complement-mediated HCV binding to B cells could be demonstrated using other commonly used cell culture-produced viruses, specifically JFH1 virus (HCV genotype 2a) and chimeric JFH1/1a virus. As shown in Fig. 7, both these well-characterized viral strains became much more

efficiently bound to B cells ($P < 0.0001$) after mixing with complement-active serum samples.

Enhanced HCV binding to Raji cells was also mediated by complement system.

We also investigated whether complement-mediated HCV binding to B cells could be demonstrated by replacing human B cells with Raji cells, a cultured B cell line derived from Burkitt's lymphoma. As shown in Fig. 8A, cell culture-produced HCV became much more efficiently bound to Raji cells after treatment of virus with complement-active serum samples either at 25°C or at 37°C as compared to the untreated samples. We also demonstrated that pre-incubation of Raji cells with anti-CD21 or anti-CD19 antibody could block the subsequent binding of complement-activated HCV to the cells (Fig. 8B). Pre-incubation of Raji cells with anti-CD81 antibody did not prevent complement-activated HCV binding to the cells (Fig. 8B), as we had also observed in PBMCs isolated from 40% of healthy blood donors.

Discussion

In our previous study of the association of HCV with PBMCs, we found no evidence that HCV replicates in PBMCs (10), but rather that HCV binds to PBMCs and preferentially to B cells. Further, we found that normal PBMCs could be made to simulate PBMCs from HCV infected patients simply by mixing them with HCV-positive plasma. Thus, it appeared that HCV could adhere to PBMC/B-cells without necessarily infecting them, suggesting that the binding was a more generalized phenomenon of B-cell interactions rather than a specific effect of HCV.

To elucidate the mechanism of preferential association of HCV with B cells, we began the investigation by using in vitro cell culture produced HCV particles mixed with PBMCs from healthy donors for in vitro binding assays, followed by fractionation of CD19+ B cells and HCV quantification by qPCR. In the absence of exogenous serum factors, there was negligible binding of culture-produced HCV particles to B cells. However, upon pre-incubation of culture-produced HCV particles with serum, HCV binding to B cells was increased by more than two orders of magnitude compared to virus in the absence of serum. The essential serum factors were found to be heat-labile and present in both healthy blood donors and HCV recovered patients, suggesting that complement might be integral to the binding process.

By using various antibodies against complement C3 proteins in the B-cell binding assays, we demonstrated that several anti-C3 mouse monoclonal antibodies, particularly anti-C3d antibody, effectively blocked the binding of HCV to B cells.

C3d is the surface-bound end-product of the proteolytic cleavage of C3b deposited on invading microorganisms during the complement activation process that splits C3 to C3a and C3b (21-25). In reconstitution experiments with

complement-depleted serum samples and the respective purified complement proteins, we demonstrated that the preferential binding of HCV particles to B

cells in PBMCs is indeed mediated by the complement system as complement

components involved in the classical pathway (C1q, C2, C3 and C4) were

required for the binding of HCV particles to B cells. In addition, the alternative

pathway and the mannose-binding lectin pathway of complement activation could

also be involved in this process (22). The generation of C3d is essential for the

opsonization of HCV particles leading to their attachment to B cells. We propose

that C3d attached to viral particles will have high affinity for complement receptor

2 (CR2; CD21) on the surface of B cells. CR2 is highly expressed in B cells and

follicular dendritic cells (22, 24). In our current assay system, there was no

significant change of HCV genomic copy numbers in the culture supernatant

before and after complement treatment as determined by qPCR (data not shown),

which implies that HCV particles are not lysed, but rather opsonized by

complement activation. Although previous reports have shown that HCV core

protein can bind to gC1q receptor (gC1qR) specific for the globular heads of the

C1q protein (26), this mechanism would not explain why HCV particles are preferentially bound to B cells since this receptor is widely distributed in all leukocyte subsets and platelets (27). Further, the preferential binding of HCV to B cells only happens when exogenous serum with complement activity is added to the virus supernatant and thus is not related to a virus-specific protein per se. In the C5-depleted serum reconstitution experiment, we found that C5 protein is not required for the preferential binding of HCV to B cells. Again this indicates that HCV particles are opsonized, and not lysed through a membrane attack complex. However, when excess of the purified C5 protein was present in reconstituted C5-depleted serum, the binding of HCV to B cells was significantly decreased suggesting that complement-mediated viral lysis may have occurred (Fig 4).

There are at least ten receptors for complement components, fragments, and complexes (22, 27). To further elucidate the mechanism of preferential binding of HCV to B cells, we used various antibodies against cell surface receptors in the assay system to assess the effectiveness of each antibody in blocking HCV binding to B cells. As shown in Fig. 5, anti-CD21 displayed the strongest activity in blocking HCV binding to B cells, followed by anti-CD20, anti-CD35, and anti-CD81. CD21 is complement receptor 2 (CR2), and the receptor for C3d (27). CD21 usually forms a complex with CD19 and CD81 on the surface of B cells (28). CD35 is complement receptor 1 (CR1), and it has dual roles as complement

receptor and complement regulator (27). The ligands for CR1 are C3b and C4b.

In this study, we found that anti-CD81 antibody only blocked HCV binding to B cells in 60% of PBMCs tested from 10 individuals. This could be due to polymorphic CD81 antigen expression on B cells from different individuals. Anti-CD81 antibody also did not block HCV binding to Raji cells (Fig. 8B). The preferential binding of HCV to B cells was shown not only for HCV particles produced in cell culture, but also for HCV particles derived directly from three chronically infected patients. Whether using culture-derived or patient-derived HCV, binding to B cells was blocked more efficiently by anti-CD21 (complement receptor 2) than by anti-CD35 (complement receptor 1). Similar finding of human immunodeficiency virus 1 (HIV-1) binding to B cells through CD21-complement interactions has been reported (29).

The complement system plays a central role in innate immune defense and consists of both soluble factors and cell surface receptors that interact to sense and respond to a wide range of invading microorganisms. Activation of complement system has been demonstrated during infection by several enveloped viruses including HIV-1 (24), herpesvirus (30), Ebola virus (31), and influenza virus (32). However, these viruses have also evolved escape mechanisms to evade the complement system by incorporating host regulators of complement activation into their viral envelopes and, as a result, escape antibody-dependent complement-mediated virus lysis (30, 33). Complement

activation upon HCV infection has been implicated in several studies (34-36). In addition, CD55 and CD59, regulators of complement activation, were shown to be incorporated into HCV virions (37, 38), which led to resistance to complement-mediated antibody-dependent virolysis. In the present study, we demonstrated that HCV particles either produced by in vitro cell culture system or directly from chronic HCV patients were opsonized, but not lysed by complement activation, which eventually led to preferential association of HCV particles with B cells in PBMC. Although not investigated in this study, in chronic HCV patients, complement receptor 1/CD35 on erythrocytes may also play a key role in transporting complement-mediated, opsonized HCV immune-complexes. In this study, we mainly investigated antibody-independent activation of the complement system by HCV. In chronic HCV infection, antibody-dependent complement activation may play a more complex role and interplay with many other types of cells, as seen in HIV infection (24).

Epidemiological studies have demonstrated an increased risk of developing B-cell non-Hodgkin lymphoma (B-NHL) in patients with chronic HCV infection (39, 40). B-NHL subtypes frequently associated with HCV are marginal zone lymphoma, lymphoplasmacytic lymphoma, and diffuse large B-cell lymphoma.

The most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication with interferon- α monotherapy or in combination with ribavirin (39, 40).

However, the strength of the association shows great geographic discrepancies, with higher relative risk in countries with high HCV prevalence. Three general hypotheses have been proposed to elucidate HCV-induced lymphomagenesis (39): 1) Continuous external stimulation of lymphocyte receptors by viral antigens throughout persistent infection; 2) HCV replication in B cells with oncogenic effect mediated by intracellular viral proteins; 3) permanent B-cell damage by mutation of tumor suppressor genes caused by a transiently present intracellular virus (41). The lymphoma subtypes associated with HCV infection originate from germinal center or post-germinal center lymphocytes, suggesting a possible antigen-driven proliferation (40). Indeed, a monoclonal/oligoclonal B-cell expansion has been shown in circulating B cells, as well as in the bone marrow or intrahepatic B cells of chronic HCV patients (42). However, the strongly biased immunoglobulin gene usage by abnormal B cells in HCV-associated mixed cryoglobulinemia (43) and in HCV-associated lymphomas (44, 45), as well as the inability of lymphoma BCRs from patients with B-NHL and chronic HCV infection to bind HCV antigens (46), may indicate that lymphoma formation in HCV infection is a complex process in which persistent antigenic stimulation through complement-mediated binding plays only an indirect, and as yet undefined role. Our results support the notion that chronic HCV infection can potentially promote lymphomagenesis through complement-mediated preferential binding of HCV to B cells, which generates a complex by combining C3d-tagged HCV with CD19 and CD81. This complex can then bring B-cell antigen receptors together into lipid rafts and lower

the threshold for B-cell activation and proliferation (47, 48). Further investigation of signaling pathways involved in complement-mediated HCV binding to B cells is warranted.

Acknowledgments:

We thank Dr. Francis Chisari for providing us with Huh-7.5.1 cells, Dr. Stanley Lemon for providing us with H77S plasmids, and Dr. Jake Liang for providing us with JFH-1 virus and JFH1/1a chimeric virus.

References

1. **Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali EI Din Z.** Hepatitis C virus: A global view. *World J Hepatol* 2015;7:2676-2680.
2. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. *Hepatology* 2006;44:15-22.
3. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. *World J Hepatol* 2015;7:327-343.

4. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. *Kidney Int* 2009;76:818-824.
5. Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. *Lupus* 2015;24:469-482.
6. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. *Hepatology* 2009;49:1431-1441.
7. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Burse FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. *Gastroenterology* 2008;134:812-822.
8. **Pham TN, Michalak TI.** Occult persistence and lymphotropism of hepatitis C virus infection. *World J Gastroenterol* 2008;14:2789-2793.
9. Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. *Dig Liver Dis* 2007;39 Suppl 1:S38-45.
10. Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. *Hepatology* 2013;57:483-491.
11. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? *Hepatology* 2009;49:665-675.

12. Boisvert J, He XS, Cheung R, Keeffe EB, Wright T, Greenberg HB. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. *J Infect Dis* 2001;184:827-835.
13. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. *J Infect Dis* 1997;176:1209-1214.
14. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, Dragic T. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. *J Virol* 2008;82:3555-3560.
15. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. *Hepatology* 2007;46:1722-1731.
16. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, Rice CM, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. *Hepatology* 2008;48:1843-1850.
17. **Rosa D, Saletti G, De Gregorio E**, Zorat F, Comar C, D'Oro U, Nuti S, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. *Proc Natl Acad Sci U S A* 2005;102:18544-18549.
18. Stamataki Z, Shannon-Lowe C, Shaw J, Mutimer D, Rickinson AB, Gordon J, Adams DH, et al. Hepatitis C virus association with peripheral blood B

lymphocytes potentiates viral infection of liver-derived hepatoma cells. *Blood* 2009;113:585-593.

19. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. *Annu Rev Immunol* 1995;13:127-149.

20. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. *Science* 1992;256:105-107.

21. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway--its role in innate immunity and evolution. *Immunol Rev* 2004;198:185-202.

22. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. *Nat Immunol* 2010;11:785-797.

23. Stoermer KA, Morrison TE. Complement and viral pathogenesis. *Virology* 2011;411:362-373.

24. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. *Vaccine* 2008;26:3046-3054.

25. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, et al. Detection of complement activation using monoclonal antibodies against C3d. *J Clin Invest* 2013;123:2218-2230.

26. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. *J Virol* 2004;78:6409-6419.

27. Morgan BP. The complement system: an overview. *Methods Mol Biol* 2000;150:1-13.
28. Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. *Curr Opin Immunol* 2005;17:237-243.
29. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, Baseler M, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. *J Exp Med* 2000;192:637-646.
30. Lee MS, Jones T, Song DY, Jang JH, Jung JU, Gao SJ. Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. *PLoS Pathog* 2014;10:e1004412.
31. Mason CP, Tarr AW. Human lectins and their roles in viral infections. *Molecules* 2015;20:2229-2271.
32. **Monsalvo AC, Batalle JP, Lopez MF**, Krause JC, Klemenc J, Hernandez JZ, Maskin B, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. *Nat Med* 2011;17:195-199.
33. **Hu W, Yu Q**, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. *J Immunol* 2010;184:359-368.
34. Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. *Protein Cell* 2010;1:664-674.

35. Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, et al. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. *J Innate Immun* 2014;6:676-684.
36. Kim H, Meyer K, Di Bisceglie AM, Ray R. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. *J Virol* 2013;87:5858-5867.
37. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N, Grantham A, Liu Z, et al. CD59 incorporation protects hepatitis C virus against complement-mediated destruction. *Hepatology* 2012;55:354-363.
38. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Diamond MS, et al. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. *J Virol* 2013;87:7902-7910.
39. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. *J Hepatol* 2013;59:169-177.
40. Vannata B, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. *Hematology Am Soc Hematol Educ Program* 2014;2014:590-598.
41. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. *Proc Natl Acad Sci U S A* 2004;101:4262-4267.

42. **Weng WK, Levy S.** Hepatitis C virus (HCV) and lymphomagenesis. *Leuk Lymphoma* 2003;44:1113-1120.
43. **Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, Russo G, et al.** Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. *J Immunol* 2005;174:6532-6539.
44. **Chan CH, Hadlock KG, Fong SK, Levy S.** V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. *Blood* 2001;97:1023-1026.
45. **Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Cuoghi A, et al.** Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. *Am J Pathol* 2001;159:253-261.
46. **Ng PP, Kuo CC, Wang S, Einav S, Arcaini L, Paulli M, Portlock CS, et al.** B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. *Blood* 2014;123:1512-1515.
47. **Niemann CU, Wiestner A.** B-cell receptor signaling as a driver of lymphoma development and evolution. *Semin Cancer Biol* 2013;23:410-421.
48. **Pierce SK.** Lipid rafts and B-cell activation. *Nat Rev Immunol* 2002;2:96-105.

Author names in bold designate shared co-first authorship.

Figure legends

Fig. 1. Serum samples from both healthy blood donors and HCV recovered subjects can promote HCV binding to B cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml medium were incubated with 100 μ l serum sample at room temperature for 1 h, followed by mixing with 2 ml PBMCs (2.5×10^7 cells/ml) in complete RPMI medium. The reaction was carried out at 37°C for 2 h. The cells then were processed for separation into B and non-B fractions by using CD19 magnetic microbead column purification as described in Methods section. A negative control that did not incubate virus with serum was included in this study but not plotted in this figure; this control had an HCV viral load on B cells of 411 copies per μ g total RNA. Each value represents the mean of triplicate determinations.

Fig. 2. Heat-labile components in human serum promote the binding of HCV to B cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml medium were incubated with 100 μ l serum sample or heat-inactivated serum sample (56°C for 30 min) at room temperature for 1 h, followed by mixing with 2 ml PBMCs (2.5×10^7 cells/ml) in complete RPMI medium. The reaction was carried out at room temperature (25°C) for 1 h. The cells then were processed for HCV quantification as described in Methods section. Each value represents the mean

± SD of 9 determinations. The experiments were repeated twice with similar results using PBMCs from two different donors.

Fig. 3. Antibodies against complement C3 protein can block HCV binding to B cells. Twenty-five µl serum sample was incubated with 20 µg of the indicated mouse monoclonal antibody (clones C4, B9, and 2898) against complement C3 protein and C3d (clone 003-05) at 25°C for 30 min, followed by mixing with virus and incubating at 25°C for 1 h. After mixing with PBMC, the mixture was incubated at 25°C for one more hour. The cells then were processed for HCV quantification as described in Methods section. The most potent inhibitory of binding was observed with anti-C3d. Each value represents the mean ± SD of 6 determinations. The experiments were repeated three times with similar results using PBMCs from three different donors.

Fig. 4. Purified complement proteins C1q, C2, C3, and C4 added to the indicated complement-depleted (Dpl) serum can restore HCV binding to B cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml medium were incubated with 100 µl of the indicated complement-depleted serum sample or complement-depleted serum sample plus the indicated purified complement protein, or purified complement protein only. After 1h incubation at 25°C, 2 ml PBMCs (2.5×10^7 cells per ml) in complete RPMI medium was added. The reaction was


carried out at room temperature (25°C) for 1 h. The cells then were processed for HCV quantification as described in Methods section. All experiments were repeated twice with similar results using PBMCs from two different donors. Each value represents the mean \pm SD of 6 determinations.

Fig. 5. Receptors involved in complement-mediated HCV binding to B cells. Two ml of PBMCs (2.5×10^7 cells/ml) were incubated with 10 μ g of the indicated antibody at 25°C for 0.5 h; followed by mixing with 3 ml of activated virus (pre-incubation with serum for 1 h at 25°C, 1×10^7 genomic copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification as described in Methods section. **: $P < 0.01$, ***: $P < 0.001$, ****: $P < 0.0001$; when the reduction of HCV binding to B cells by the indicated antibody was compared to antibody isotype control. Each value represents the mean \pm SD of 6 determinations. The experiments were repeated three times with similar results using PBMCs from three different donors. CD11b is part of complement receptor 3, CD20 is one of major B cell markers, CD21 is also known as complement receptor 2, CD32 is receptor for Fc fragment of immunoglobulin G, CD35 is complement receptor 1, and CD55 is membrane-bound decay-accelerating factor for convertases of complement system.

Fig. 6. Anti-CD21 and anti-CD35 antibodies can block the binding of HCV viruses from chronically infected patients to B cells. Two ml of PBMCs (2.5×10^7 cells/ml) were incubated with 10 μ g of the indicated antibody at 25°C for 0.5 h; followed by mixing with 3 ml of the indicated 15-fold diluted virus (pre-incubation for 0.5 h at 25°C, $3\text{-}5 \times 10^6$ genomic copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations. The experiments were repeated twice with similar results using PBMCs from two different donors.

Fig. 7. Complement-mediated HCV binding to B cells worked on in vitro cultured HCV 1a and HCV 2a viruses. Three ml of the indicated virus (HCV1a, 1×10^7 copies total; HCV2a, 1×10^8 copies total; JFH1/1a, 3×10^7 total) were treated either with 100 μ l medium only as control or 100 μ l serum at 25°C for 1 h, followed by mixing with 2 ml PBMCs (2.5×10^7 cells per ml) in complete RPMI medium. The reaction was carried out at room temperature (25°C) for 2 h. The cells then were processed for HCV quantification as described in Methods section. ****: $P < 0.0001$ when compared to without serum treatment for each virus. Each value represents the mean \pm SD of 6 determinations.


Fig. 8. Complement-mediated HCV binding to Raji cells. (A) HCV genotype 1a virus in 3 ml medium was incubated with 100 μ l serum sample or medium only at 25°C for 1 h, followed by mixing with 2 ml of Raji cells (1×10^6 cells/ml) and incubating at the indicated temperature for 1 h. (B) 2 ml of Raji cells (1×10^6 cells/ml) were incubated with 10 μ g each of the indicated antibody at room temperature for 30 min, followed by mixing with 3 ml of complement-activated HCV genotype 1a virus (pre-incubation with serum for 1 h at 25°C, 1×10^7 genomic copies per reaction), and incubating at 25°C for 1 h. After incubation, the cells were pelleted, washed two times with complete RPMI medium, and processed for RNA isolation and HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations.



258x179mm (300 x 300 DPI)

Accepted


Fig. 2



196x168mm (300 x 300 DPI)

Accepted


Fig. 3



188x184mm (300 x 300 DPI)


Acce

Fig. 4




247x165mm (300 x 300 DPI)

Accepte




270x194mm (300 x 300 DPI)

Accept




251x88mm (300 x 300 DPI)

Accepted A



188x165mm (300 x 300 DPI)

Accel



254x123mm (300 x 300 DPI)

Accepted

Supplementary Information

Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System

Richard Y. Wang, Patricia Bare, Valeria De Giorgi, Kentaro Matsuura, Kazi Abdus Salam, Teresa Grandinetti, Cathy Schechterly, Harvey J. Alter

Supporting Methods:

Cell culture

The human hepatoma cell line, Huh7.5.1 was obtained from Dr. Francis V. Chisari (1). Huh7.5.1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat inactivated fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES, pH7.2, 100 unit/ml penicillin, 100 µg/ml streptomycin, and 1% non-essential amino acids (Thermo Fisher Scientific, Waltham, MA) in a humidified 37°C, 5% CO₂ incubator. PBMCs and Raji cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum, 2 mM L-glutamine, 100 unit/ml penicillin, and 100 µg/ml streptomycin (complete RPMI medium).

In-vitro RNA synthesis

The plasmid pH77-S, which carries a full length HCV1a sequence with five cell culture-adaptive mutations was kindly provided by Dr. Stanley Lemon (2). The plasmid was linearized with XbaI restriction enzyme and purified by Qiagen PCR purification kit. In

in vitro transcribed RNA, using the MEGA-script T7 kit (Thermo Fisher Scientific, Waltham, MA), was purified with Qiagen RNA clean up kit. The RNA pellet was aliquoted and stored at -80°C until use.

HCV production in cell culture

1.4 μg of HCV1a (H77S) full length RNA was transfected into 2×10^5 Huh7.5.1 cells per well in 6-well plates by using mRNA boost reagent and TransIT-mRNA reagent (Mirus, MIR2250) according to the manufacturer's instructions. Six hours after transfection, the cells were trypsinized, washed once with complete DMEM medium without antibiotics, and collected by centrifugation. Cells were seeded into 25x150mm culture dishes at 1.2×10^6 cells per dish with 50 ml complete DMEM medium without antibiotics. After incubation for 6 days, the culture supernatant was collected and filtered through $0.45\mu\text{m}$ sterile filtration units. The filtrates were aliquoted and stored at -80°C before use. The virus producing cells were continuously sub-cultured every 3-4 days for 21 days post transfection by seeding 4×10^6 cells per 25x150mm culture dish with 50 ml complete DMEM medium and collecting the culture supernatant after 72 h incubation. For the production of HCV genotype 2a virus, 5×10^6 Huh-7.5.1 cells in each 25x150mm culture dish were infected with JFH1 virus at $\text{MOI}=0.1$. The culture supernatant was collected 96 h post infection and centrifuged at 1,800 rpm for 10 min. The supernatant was filtered through $0.45\mu\text{m}$ sterile filtration units. The filtrates were aliquoted and stored at -80°C before use. For the production of JFH1/1a chimeric virus, 3×10^6 Huh-7.5.1 cells in each 25x150mm culture dish were infected with JFH1/1a virus at $\text{MOI}=0.1$. After 96 h infection, the cells were sub-cultured at $7-8 \times 10^6$ cells per 25x150mm culture dish with 50 ml complete DMEM medium. The culture supernatant was collected 24 h later and

centrifuged at 1,800 rpm for 10 min. The supernatant was filtered through 0.45µm sterile filtration units. The filtrates were stored at -80°C before use.

Conversion of plasma samples to serum samples

Some HCV patients' blood samples and healthy blood donor samples were received as plasma samples. To convert plasma samples to serum samples, CaCl₂ was added first to the plasma samples at 10 mM final concentration, mixed, and followed by adding thrombin (Sigma-Aldrich, St. Louis, MO) at final 0.1unit/ml. The samples were incubated at 37°C for 0.5 h, followed by incubating at room temperature for 0.5 h, and then stored at -20°C overnight. The samples were thawed in a 37°C water bath, and the clots were removed and squeezed for residual fluid using sterile forceps in a biosafety hood. The serum samples were further incubated in ice for one hour. If no clot was detected, 1 ml aliquots were prepared and stored at -80°C.

PBMCs and PBMC subset separation

PBMCs were isolated by Ficoll-Paque density gradient centrifugation from buffy coat. Each buffy coat (about 18-30 ml) was diluted with 1X PBS, pH7.4 to 120 ml, and divided equally into four sterile 50 ml conical tubes. Each tube was then underlay with 15 ml of Ficoll-Paque Plus solution (GE Healthcare Life Sciences, Marlborough, MA), and centrifuged at 400 x g for 30 min at 25°C. The lymphocytes were collected from the interphase layer and washed twice with 1X PBS, pH7.4. The cells were pelleted by centrifugation at 400 x g and 200 x g for 10 min each at 25°C for the first wash and the second wash, respectively. The cells were further washed once with complete RPMI medium and collected by centrifugation at 200 x g for 10 min at 25°C. The B cell subset

was purified by positive selection using MACS magnetic beads coated with anti-human CD19 antibody (Miltenyi Biotec Inc., Auburn, CA). The efficiency of separation was > 85% for B cells as confirmed by FACS analysis (BD Biosciences, San Diego, CA). For isolation of untouched B cells from PBMCs, human B cell isolation kit II (Miltenyi Biotec Inc., Auburn, CA) was used according to the manufacturer's instructions.


In vitro HCV binding assay

For assessing the effect of anti-complement C3 antibodies on blocking HCV binding to B cells, 25 μ l of complement active serum sample was mixed with 10-20 μ g each of anti-C3 antibodies as indicated in the figure legend and incubated at 25°C for 30 min before adding 3 ml virus to the reaction mixture. All the anti-C3 antibodies used in this study were from Santa Cruz Biotechnology (Dallas, TX). For conducting HCV binding assays using complement depleted sera reconstituted with purified complement proteins, 100 μ l of the indicated complement-depleted serum was used for each reaction. All the complement-depleted sera and the purified complement proteins used in this study were obtained from Complement Technology (Tyler, TX). To measure the effect of antibodies against various cell surface receptors on HCV binding to B cells, 2 ml of PBMCs ($4-5 \times 10^7$ cells) or 2 ml of untouched B cells ($2-4 \times 10^6$ cells) were incubated with 10 μ g of mouse monoclonal antibodies against the indicated receptors at 25°C for 30 min, followed by adding 3 ml of complement activated virus and incubating for 1 h. All the antibodies for blocking cell surface receptors used in this study were obtained from BD Biosciences (San Diego, CA) except that a few anti-CD19 and anti-CD81 antibodies from Santa Cruz Biotechnology (Dallas, TX) were also tested. The clone numbers for antibodies from BD Biosciences are as follows: CD11b, ICRF44; CD19,


HIB19; CD20, 2H7; CD21, 1048; CD32, 3D3; CD35, E11; CD55, IA10; and CD81, JS-81. The clone numbers for antibodies from Santa Cruz Biotechnology are as follows: C3, C-4, B-9 and 2898; C3d, 003-05; and CD81, 1.3.3.22. C3 (C-4) and C3 (B-9) are raised against amino acids 541-840 of human C3. C3 (2898) is raised against the C-terminus of human C3. C3d (003-05) is raised against full length native C3 of human origin. The epitope mapping for anti-CD21 and anti-CD35 has been previously reported (3, 4). For determination of HCV binding to Raji cells, Raji cells were cultured in complete RPMI medium until the cell density reached to $1-2 \times 10^6$ cells per ml. The cells were then collected by centrifugation at $200 \times g$ for 10 min at 25°C . After removing the supernatant, the cells were re-suspended in complete RPMI medium and adjusted to 1×10^6 cells per ml before use.

HCV detection


For quantifying HCV genomic copy number in purified total cellular RNA samples, we used the primers and probes as previously described (5). Each sample was quantified in triplicate using a TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific, Waltham, MA) with $10 \mu\text{l}$ RNA input per reaction in a $50 \mu\text{l}$ mixture. The reactions were carried out on ABI 7900HT system with a program of 50°C for 2 min, 60°C for 30 min, 95°C for 3 min, and then 50 cycles at 95°C for 20 sec and 60°C for 1 min. The copies of HCV RNA were determined by in vitro transcribed HCV1a RNA standards (6) with the Sequence Detector Software (version 2.2; Applied Biosystems) and normalized to $1 \mu\text{g}$ total RNA input.




Supporting Fig. S1. Titrating the amount of C3d antibody needed to block HCV binding to B cells. Twenty-five μl serum sample was incubated with the indicated amount of mouse monoclonal antibody C3d (clone 003-05) at 25°C for 30 min, followed by mixing with virus and incubating at 25°C for 1 h. After mixing with PBMC, the mixture was incubated at 25°C for one more hour. The cells then were processed for HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations.




Supporting Fig. S2. A combination of purified complement proteins C1, C2, C3, and C4 can restore HCV binding activity to B cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml medium were incubated with the indicated purified complement protein(s). The amount of each protein used was as follows: C1, 25 μ g; C2, 5 μ g; C3, 60 μ g; and C4, 25 μ g. For positive control serum, 100 μ l was used in each reaction. After 0.5 h incubation at 25°C, 2 ml PBMCs (2.5×10^7 cells per ml) in complete RPMI medium was added. The reaction was carried out at room temperature (25°C) for 1 h. The cells then were processed for HCV quantification as described in Methods section. The values for C1, C2, C3, or C4 only reaction represent the mean \pm SD of 3 determinations. The values for a combination of two or more of C1, C2, C3, or C4 reaction represent the mean \pm SD of 6 determinations.



Supporting Fig. S3. Titration of antibody concentration of anti-CD21 (complement receptor 2) in complement-mediated HCV binding to B cells. Two ml of PBMCs (2.5×10^7 cells/ml) were incubated with the indicated amount of anti-human CD21 antibody (clone 1048) or isotype control antibody at 25°C for 0.5 h; followed by mixing with 3 ml of activated virus (pre-incubation with serum for 0.5 h at 25°C , 1×10^7 genomic copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations.



Supporting Fig. S4. Lowering the concentration of antibodies to receptors involved in complement-mediated HCV binding to B cells. Two ml of PBMCs (2.5×10^7 cells/ml) were incubated with 1 μ g of the indicated antibody at 25°C for 0.5 h; followed by mixing with 3 ml of activated virus (pre-incubation with serum for 0.5 h at 25°C, 1×10^7 genomic copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations.



Supporting Fig. S5. Receptors involved in complement-mediated HCV binding to B cells. Two ml of untouched B cells (1.0×10^6 cells/ml) were incubated with 10 μg of the indicated antibody at 25°C for 0.5 h; followed by mixing with 3 ml of activated virus (pre-incubation with serum for 1 h at 25°C, 1.5×10^7 genomic copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification as described in Methods section. Each value represents the mean \pm SD of 6 determinations. The experiments were repeated three times with similar results using untouched B cells from three different donors.

References

1. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, et al. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci U S A* 2005;102:9294-9299.
2. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc Natl Acad Sci U S A* 2006;103:2310-2315.
3. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, et al. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. *J Immunol* 2001;167:5758-5766.
4. Nickells M, Hauhart R, Krych M, Subramanian VB, Geoghegan-Barek K, Marsh HC, Jr., Atkinson JP. Mapping epitopes for 20 monoclonal antibodies to CR1. *Clin Exp Immunol* 1998;112:27-33.
5. Zhang L, Alter HJ, Wang H, Jia S, Wang E, Marincola FM, Shih JW, et al. The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-kB mediated interferon beta response in Huh7.5.1 cells. *Virology* 2013;438:28-36.
6. Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. *Hepatology* 2013;57:483-491.